Lincoln Capital Corp Invests $204,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Lincoln Capital Corp bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 1st quarter, HoldingsChannel reports. The fund bought 3,000 shares of the company’s stock, valued at approximately $204,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Congress Asset Management Co. MA boosted its position in shares of CRISPR Therapeutics by 60.3% in the first quarter. Congress Asset Management Co. MA now owns 64,605 shares of the company’s stock worth $4,403,000 after buying an additional 24,303 shares during the period. PBCay One RSC Ltd acquired a new stake in CRISPR Therapeutics during the fourth quarter valued at $10,329,000. Invesco Ltd. boosted its position in CRISPR Therapeutics by 1.5% during the third quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock valued at $6,179,000 after purchasing an additional 2,061 shares during the last quarter. ARK Investment Management LLC boosted its position in CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after purchasing an additional 1,372,986 shares during the last quarter. Finally, Norges Bank acquired a new stake in CRISPR Therapeutics during the fourth quarter valued at $38,661,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Buying and Selling

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded down $1.15 during trading hours on Friday, hitting $54.23. 364,196 shares of the company’s stock were exchanged, compared to its average volume of 1,642,986. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10. The stock has a market capitalization of $4.61 billion, a price-to-earnings ratio of -20.03 and a beta of 1.78. The company’s 50-day moving average price is $56.74 and its 200-day moving average price is $64.51.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. During the same period in the previous year, the company earned ($0.67) earnings per share. The business’s revenue was down 99.5% compared to the same quarter last year. On average, research analysts expect that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CRSP shares. Robert W. Baird lifted their price objective on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Oppenheimer reduced their price objective on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. Barclays reduced their price objective on CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 price target on shares of CRISPR Therapeutics in a research report on Monday, June 17th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $75.71.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.